Roche Licenses PI3K Biomarker from Qiagen to Create PCR-Based Dx Assays for Rx Development

Sharing a co-exclusive license to PI3K with Qiagen, Roche will develop assays for diagnostic markers to help subsidiary Genentech and external pharma partners to advance investigational drug candidates that inhibit PI3K.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.